Srdan Verstovsec
LONDON—Strikingly successful treatment results were reported in patients with myelofibrosis — a disabling, disfiguring and fatal cancer, for which no therapy has been available up to now — at the European Haematology Association annual meeting held in London (June 8-12, 2011). Srdan Verstovsek from the MD Anderson Cancer Center in Texas tells ecancer radio about his group’s data from a placebo-controlled study investigating treatment with the monoclonal antibody ruxolitinib which inhibits the JAK II enzyme. Organomegaly was reversed and symptoms reduced in the COMFORT I and COMFORT II studies.
More news from the EHA congress at http://www.ecancermedicalscience.com.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
One Comment
Our 3,000 subscribers to mpdsupport.org or bit.ly/joinmpdsupport, have been waiting decades for this dramatic news. Ruxolitinib will likely be the very first JAK2 to receive FDA approval with more JAK2′s to follow. Bless you Dr. Verstovsec.